rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-1-83-86rpcardio-603Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯONCE AGAIN ABOUT BETA-ADRENOBLOCKERS IN ARTERIAL HYPERTENSION. WHAT SHOULD DOCTOR RECOMMEND TO THE PATIENT?И ВНОВЬ О БЕТА-АДРЕНОБЛОКАТОРАХ ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ. ЧТО ЖЕ РЕКОМЕНДОВАТЬ ПРАКТИЧЕСКОМУ ВРАЧУ?МарцевичС. Ю.MartsevichS. Y.

101990 Москва, Петроверигский пер., 10

Кафедра доказательной медицины 

Petroverigsky per. 10, Moscow, 101990

Chair of Evidence Based Medicine

smartsevich@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины Росмедтехнологий, Московская медицинская академия им. И.М.СеченоваРоссияState Research Center for Preventive Medicine of Rosmedtechnology, Moscow Medical Academy named after I. M. SetchenovRussian Federation200908012016518386Copyright © Martsevich S.Y., 20162016Марцевич С.Ю.Martsevich S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/603

The role of beta-blockers (BB) in arterial hypertension therapy is discussed from the evidence based medicine point of view and according to international guidelines. Data of the latest meta-analysis comparing effects of BB and other antihypertensive drugs on a probability of cardio-vascular complications are presented. 

Анализируется роль бета-блокаторов (ББ) в лечении артериальной гипертонии с позиций доказательной медицины и международных клинических рекомендаций. Представлены данные последних мета-анализов, сравнивавших влияние ББ и других классов антигипертензивных препаратов на вероятность сердечно-сосудистых осложнений.

артериальная гипертониябета-адреноблокаторыдоказательная медицинаarterial hypertensionbeta-adrenoblockersevidence based medicineReferencesMRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). IPPPSH Collaborative Group. J Hypertens 1985;3:379-92.Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). IPPPSH Collaborative Group. J Hypertens 1985;3:379-92.Wilhelmsen L, Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.Wilhelmsen L, Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991;17:579-88.Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991;17:579-88.Medical Research Council trial of treatment of hypertension in older patients: principal results. MRC Working Party. BMJ 1992;304:405-12.Medical Research Council trial of treatment of hypertension in older patients: principal results. MRC Working Party. BMJ 1992;304:405-12.Hansson L., Lindholm L., Dahlof B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.Hansson L., Lindholm L., Dahlof B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.Dahlof B., Devereux R., Kjeldsen S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002;359:995-1003.Dahlof B., Devereux R., Kjeldsen S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002;359:995-1003.Dahlof B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895- 906.Dahlof B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895- 906.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.Turnbull F; Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.Turnbull F; Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.Lindholm L., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.Lindholm L., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.Elliott W., Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.Elliott W., Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121-3.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121-3.Bangalore S., Wild D., Parkar S., et al. Beta-blockers for primary prevention of heart failure in patients with hypertension. J Am Coll Cardiol 2008;52:1062-72.Bangalore S., Wild D., Parkar S., et al. Beta-blockers for primary prevention of heart failure in patients with hypertension. J Am Coll Cardiol 2008;52:1062-72.Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.Messerli F., Bell D., Fonseca V. et al. Body weight changes with β-blocker use: results from GEMINI. Am J Med 2007;120:610-5.Messerli F., Bell D., Fonseca V. et al. Body weight changes with β-blocker use: results from GEMINI. Am J Med 2007;120:610-5.Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.Prisant L.M., Neutel J.M., Papademetriou et al. Low-dose combination treatment for hypertension versus single-drug treatment – bisoprolol/hydrochlorothiazide versus amlodopine, enalapril, and placebo: combined analysis of comparative studies. Am J Ther 1998;5:313-21.Prisant L.M., Neutel J.M., Papademetriou et al. Low-dose combination treatment for hypertension versus single-drug treatment – bisoprolol/hydrochlorothiazide versus amlodopine, enalapril, and placebo: combined analysis of comparative studies. Am J Ther 1998;5:313-21.

The authors declare that there are no conflicts of interest present.